Astrazeneca Pharma India Ltd

AstraZeneca Pharma India Limited announced that the Hon'ble High Court of Delhi has stayed the operation of a demand notice dated July 27, 2026, issued by the National Pharmaceutical Pricing Authority (NPPA) alleging overcharging for Betaloc-50 tablets, until a hearing on February 10, 2027. The NPPA alleges that AstraZeneca Pharma India Ltd. sold the medication at a price exceeding the ceiling set under the Drugs (Prices Control) Order, 2013, between June and July 2016, resulting in a demand for recovery of overcharged amounts plus interest; as part of the stay, the company is required to deposit 15% of the amount mentioned in the Demand Notice with the Registrar General of the Delhi High Court.

AstraZeneca Pharma India Limited will hold a board meeting on Monday, August 10, 2026, to consider and approve the unaudited financial results for the quarter ended June 30, 2026, the company said in a filing. The trading window for designated persons will remain closed from June 16, 2026, to August 12, 2026, in accordance with the company’s insider trading code.

The company said Agrawal stepped down following her appointment to a regional role within the AstraZeneca Group. Agrawal also ceases to be the company's Chief Financial Officer and Key Managerial Personnel (KMP) with effect from the close of business hours on August 31, 2026. The company said there are no other material disclosures relating to her resignation. Agrawal does not hold any shares in AstraZeneca Pharma India, according to the filing. AstraZeneca is a global biopharmaceutical company focused on the discovery, development, and commercialization of prescription medicines in four areas: Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Rare Diseases. It operates in over 100 countries. AstraZeneca Pharma India reported a 22.95% year-on-year decline in standalone net profit to Rs 44.88 crore for the quarter ended March 2026 (Q4 FY26), compared with Rs 58.25 crore in the corresponding quarter of the previous fiscal. Revenue from operations, however, rose 20.42% year-on-year to Rs 578.61 crore during the quarter, up from Rs 480.48 crore in the year-ago period. The scrip rose 0.08% to Rs 8,070.15 on the BSE Powered by Capital Market - Live

AstraZeneca Pharma India announced that Bhavana Agrawal, Executive Director and Chief Financial Officer (CFO) has resigned from the position of CFO (Key Managerial Personnel) of the company with effect from the close of business hours on 31 August 2026, pursuant to her appointment to a regional role within the AstraZeneca Group.

Astrazeneca Pharma India announced that the 47th Annual General Meeting(AGM) of the company will be held on 10 August 2026.

The approval is for an additional indication of Benralizumab 30 mg/ml solution for injection in a pre-filled syringe (brand name: Fasenra). The drug is now indicated for the treatment of patients aged 12 years and above with hypereosinophilic syndrome (HES) without an identifiable non-haematologic secondary cause. The receipt of this permission paves the way for the marketing of Benralizumab 30 mg/ml solution for injection in a pre-filled syringe (brand name: Fasenra) in India for the specified additional indication, subject to receipt of related statutory approvals, if any. AstraZeneca is a global biopharmaceutical company focused on the discovery, development, and commercialization of prescription medicines in four areas: Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Rare Diseases. It operates in over 100 countries. The company's standalone net profit declined 22.95% to Rs 44.88 crore in the quarter ended March 2026 as against Rs 58.25 crore during the previous quarter ended March 2025. Sales rose 20.42% to Rs 578.61 crore in the quarter ended March 2026 as against Rs 480.48 crore during the previous quarter ended March 2025. The counter slipped 1.77% to Rs 8,092 on the BSE. Powered by Capital Market - Live

AstraZeneca Pharma India has appointed Praveen K Mittal, Director - Corporate Affairs, with effect from 06 July 2026

Astrazeneca Pharma India announced that the Board of Directors of the Company at its meeting held on 26 May 2026, inter alia, have recommended the final dividend of Rs 36 per equity Share (i.e. 1800%) , subject to the approval of the shareholders.

Net profit of Astrazeneca Pharma India declined 22.95% to Rs 44.88 crore in the quarter ended March 2026 as against Rs 58.25 crore during the previous quarter ended March 2025. Sales rose 20.42% to Rs 578.61 crore in the quarter ended March 2026 as against Rs 480.48 crore during the previous quarter ended March 2025. For the full year,net profit rose 62.02% to Rs 187.52 crore in the year ended March 2026 as against Rs 115.74 crore during the previous year ended March 2025. Sales rose 32.59% to Rs 2275.58 crore in the year ended March 2026 as against Rs 1716.29 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales578.61480.48 20 2275.581716.29 33 OPM %10.5317.98 -11.5114.80 - PBDT64.82101.84 -36 286.03293.14 -2 PBT59.2284.15 -30 257.45253.15 2 NP44.8858.25 -23 187.52115.74 62 Powered by Capital Market - Live

Astrazeneca Pharma India will hold a meeting of the Board of Directors of the Company on 26 May 2026.